Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.

CONCLUSIONS: Compared to chemotherapy alone, bevacizumab combined with chemotherapy significantly improved PFS in the HER2-negative MBC patients. However, the lack of a significant OS difference remained. PMID: 31974704 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31974704?dopt=Abstract

Source: Breast Cancer - January 22, 2020 Category: Cancer & Oncology Authors: Miyashita M, Hattori M, Takano T, Toyama T, Iwata H Tags: Breast Cancer Source Type: research